Posted BY: Teresa | NwoReport

Dr. Tony Fauci has come under intense scrutiny for a series of alleged falsehoods regarding various aspects of the COVID-19 pandemic. Among the accusations leveled against him are claims that he misled the public about the virus’s origin, downplayed the significance of alternative treatments like hydroxychloroquine and ivermectin, and misrepresented the effectiveness of vaccines in preventing both infection and transmission. It has also been alleged that Fauci and his associates received numerous royalty payments from pharmaceutical companies and research organizations.

Newly obtained documents, shared by nonprofit government transparency organization Open The Books, shed light on the extent of royalty payments received by the National Institute of Health (NIH), totaling around $325 million over a 12-year period. Open The Books had been pursuing these records for almost two years through Freedom of Information Act (FOIA) requests, with the NIH resisting disclosure.

Trending: Michigan Attorney General Alerts FBI to 2020 Election Fraud Investigation

The documents revealed that both then-NIH Director Francis Collins and then-National Institute of Allergy and Infectious Diseases (NIAID) Director Dr. Anthony Fauci received royalty payments. Fauci’s payments came from companies such as Ancell Corporation, Chiron Corporation, and Santa Cruz Biotechnology Inc., while Collins received payments from entities like GeneDx, Inc., IONIS, ISIS Pharmaceuticals, Inc., and others.

These revelations add to the controversy surrounding Dr. Fauci and raise questions about potential conflicts of interest and financial ties between prominent health officials and pharmaceutical interests. Critics argue that these alleged misrepresentations and financial arrangements may have impacted public health decisions and undermined trust in the handling of the pandemic. The ongoing discussion about Dr. Fauci’s actions and statements highlights the importance of transparency, accountability, and impartiality in public health leadership, particularly during times of crisis. The release of these documents underscores the need for a thorough and unbiased investigation into the matters at hand to ensure the integrity of public health information and decision-making.